Safety monitoring during the first month of the COVID-19 national vaccination program shows “reassuring safety profiles” for the Pfizer and Moderna COVID-19 vaccines, the Centers for Disease Control and Prevention reported today.

Emergency use authorizations for the vaccines require providers to report adverse events to the Vaccine Adverse Event Reporting System. About 91% of VAERS reports between Dec. 14, 2020, and Jan. 13, 2021, were for non-serious events and involved local and systemic symptoms, the authors said. Reported cases of anaphylaxis, a life-threatening but treatable allergic reaction, totaled 4.5 per million doses administered, comparable with those reported for other vaccines, they said.

The 113 deaths reported to VAERS over the period were consistent with expected all-cause mortality and did not suggest a causal relationship with vaccination, the authors said.

Related News Articles

Headline
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…